Popular Articles

Examining The Risk Of Tuberculosis From Arthritis Medication
Treatment with anti-tumor necrosis factor (TNF) agents is recognized as a risk factor for tuberculosis (TB) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn"s disease, psoriatic arthritis and psoriasis. Most TB cases develop as a result of reactivation of a latent TB infection, and health authorities worldwide recommend screening for latent TB and treating patients before initiating anti-TNF treatment. A new study examined cases of TB associated with anti-TNF therapy and found that the risk of TB is higher for patients receiving anti-TNF monoclonal antibody therapy (infliximab or adalimumab) than for those receiving soluble TNF receptor therapy (etanercept). The study is published in the July issue of Arthritis & Rheumatism.
generic viagra
Deadly Skin Cancer Cases Hit Record High
The number of people diagnosed with the deadliest form of skin cancer has crashed through the 10,000 barrier after an alarming rise in new cases, according to the latest Cancer Research UK figures revealed today.
News of the day
Array BioPharma Advances Its Lead MEK Inhibitor Into Cancer
Array BioPharma Inc. (NASDAQ: ARRY) announced the filing of an investigational new drug (IND) application with the U.S. Food and Drug Administration to initiate a Phase 1 clinical trial in cancer patients with its most advanced wholly owned MEK inhibitor, ARRY-162. Recent research confirms that the MEK pathway acts as a central axis in the proliferation of different tumors including melanoma, non-small cell lung, head/neck and pancreatic cancers. Array plans to simultaneously develop ARRY-162 for the treatment of both cancer and inflammatory disease. Array is currently completing a worldwide Phase 2, double-blinded clinical trial with ARRY-162 in 200 patients with active rheumatoid arthritis.
Medical Devices

Medicare Part D Healthy For Enrollees

Medicare beneficiaries" activities of daily living (ADL) improved in their first year of the Medicare Part D senior prescription drug plan, according to a ground-breaking study presented at the Annual AcademyHealth meetings in Chicago today. In a study of Medicare records, University of Maryland School of Pharmacy researchers found that Part D in 2006 resulted in "small but statistically significant" improvements in the health status of previously uninsured beneficiaries and in their access to medications. Nearly two-thirds of people with no drug coverage in 2005, before the plan, enrolled in Part D in 2006, the most recent year of available files from the Medicaid Current Beneficiary Survey. "It"s a rich of information about beneficiary characteristics, health status, and activity limitations," said study leader, Amy Davidoff, PhD, research assistant professor at the School. "These individuals arguably had the most to gain from the new program, and thus represent an obvious population of policy interest." Previous studies of Part D focused mainly on enrollment patterns, ease of access and beneficiary options. "Much less is known about the impact of Part D on the health and well being of beneficiaries who enrolled. It will be years before definitive answers are available, but it is now possible to assess selected potential short-term health benefits associated with Part D," said Bruce Stuart, PhD., professor, and director of the School"s Peter Lamy Center on Drug Therapy and Aging. The study also revealed that Part D enrollees experienced twice as much improvement, 8 percent, in their financial hardships than non-enrollees, 4 percent. And, non-enrollees were 3 percent less likely to report improved health in 2006 compared to 2005, relative to enrollees. Both groups reported similar counts of ADL limitations in 2005 but they declined for Part D enrollees, and increased for non-enrollees. "Our findings suggest that in its inaugural year, the program was modestly successful in achieving its stated aims," said Stuart. "The program, now in its fourth year, needs further study to determine whether the short-term gains we identified were maintained or improved further." Medicare Part D is a federal program that subsidizes the costs of prescription drugs for Medicare beneficiaries. It is part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). Part D went into effect on January 1, 2006. The team presented two posters this morning at the AcademyHealth meetings.The study was funded by Novartis Parmaceuticals, Corp. University of Maryland Baltimore


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):